Market Overview

Galectin Therapeutics Still A Favorite Pick Of H.C. Wainwright Analysts

Share:
  • H.C. Wainwright reiterated a Buy rating and $7.00 price target on shares of Galectin Therapeutics Inc (NASDAQ: GALT) on Monday.
  • The company announced last week that it had initiated a Phase 2a Psoriasis study.
  • Shares of Galectin are down more than 1.4 percent on Monday trading.

Late last week, Galectin initiated a pilot study of GR-MD-02 in 10-patients with moderate-to-severe plaque psoriasis, a condition that affects about 2 percent of the U.S. population and is mostly untreated yet. Moreover, it should be noted that results of the Phase 1 study for NASH were also quite encouraging.

Management said it would consider the trial successful if more than half of the patients meet the primary endpoint (a 75 percent amelioration in the severity of the disease after 30 days of the final infusion).

If the results of the aforementioned pilot study are positive, analyst Yi Chen assures it could strengthen the company’s pipeline for GR-MD-02. However, his $7.00 price target currently does not take into account the value of the psoriasis drug.

On top of Phase 2a Psoriasis study, the expert notes, there is a chance that Conatus Pharmaceuticals Inc (NASDAQ: CNAT) needs to include imaging tests like the ones being evaluated in Galectin’s NASH-FX trial to meet additional endpoints required for its Phase 2 trial of oral emricasan, which enrolled “22 evaluable patients with portal hypertension and compensated liver cirrhosis that was predominantly due to NASH or HCV.”

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Latest Ratings for GALT

DateFirmActionFromTo
Feb 2019Initiates Coverage OnBuy
Oct 2017Initiates Coverage OnBuy
Oct 2017Initiates Coverage OnBuy

View More Analyst Ratings for GALT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Small Cap Analysis Price Target Reiteration Analyst Ratings

 

Related Articles (GALT + CNAT)

View Comments and Join the Discussion!

How 'Bout Them Apples? Wall Street Digs Into iPhone 6s Debut

Road Trip Smarter With These Four Essential Planning Tips